It seemed the right thing for John Furey to do—take 20 years of experience in different pharma roles, including as COO of Spark Therapeutics, and become an advisor to various companies.

But Imvax Chief Executive Officer John Furey of Bryn Mawr soon realized his passion was to stay hands-on, writes Elaine Quilici for pharmexec.com.

 “I felt I could take the experiences of what I had learned in big pharma and at Spark Therapeutics, and put my energies into a project that had a meaningful impact for patients,” said Furey.

He ended up helping a team at Imvax build on early clinical data on glioblastomas.

Imvax is a clinical-stage biotechnology company that develops personalized immunotherapies that fight tumors.

Before he knew it, he was assuming a hands-on role as Imvax CEO.

When he first came on board in 2019, the company had five people in a rented Chestnut Hill office.

Now, it has 40 on staff, working in clinical, research and development, and technical operations.

It has its own office and lab space at The Curtis Center in Center City and is building a manufacturing suite there. 

In two years, Imvax has become a fully integrated biotech company.

Read more at pharmexec.com about Imvax’s future and CEO John Furey.